- PR Newswire•4 days ago
CAMBRIDGE, Mass., Jan. 18, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (MACK) ("Merrimack" or the "Company") today announced that Richard Peters, M.D., Ph.D., has been appointed as the Company's President and Chief Executive Officer, effective February 6, 2017, at which time he will also be appointed to the Merrimack Board of Directors. Dr. Peters will join Merrimack from his current role at Sanofi Genzyme, where he serves as Senior Vice President and Head of Global Rare Diseases. He replaces Gary Crocker, Chairman and Interim President and CEO, who guided the Company during the recent restructuring process and search for a permanent CEO and will remain Chairman of the Board.
- Zacks•5 days ago
Shares of Merrimack Pharmaceuticals Inc (MACK) have increased 47.9% in the last twelve months as the company looks to restructure business.
- 24/7 Wall St.•5 days ago
DryShips, Perrigo, Merrimack, and Alcobra post new 52-week lows Tuesday.
MACK : Summary for Merrimack Pharmaceuticals, Inc. - Yahoo Finance
Merrimack Pharmaceuticals, Inc. (MACK)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Bid||2.90 x 500|
|Ask||3.03 x 2600|
|Day's Range||2.98 - 3.08|
|52 Week Range||2.96 - 9.02|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-2.19|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|